Kornimate/medical-research-clean huggingface dataset:
the outcome after lichtenstein operation vs. progrip patch repair of inguinal hernia

Conditions: Inguinal Hernia; Primary; Unilateral

Summary: for the present study, 400 consecutive men with unilateral primary inguinal hernia are randomized to lichtenstein repair using either light weight polypropylene mesh (38g/m2) or light weight progrip mesh. progrip mesh adheres to tissues with polylactic micro hooks without suturing. the primary aim is to examine, whether the progrip mesh produces less pain than sutured polypropylene mesh. secondary outcomes are operation time and convalescence as well as recurrence rate. progrip mesh is supposed to be faster to apply as no sutures are needed, which may compensate for its higher cost. the patients are blinded to which mesh they receive.


Eligibility criteria:
inclusion criteria: * primary unilateral inguinal hernia exclusion criteria: * not willing to participate * not capable to understand or fill in the questionnaires

Keywords: open mesh repair sutured non-sutured pro-grip postoperative pain
manual therapy for hand osteoarthritis

Conditions: Hand Osteoarthritis

Summary: osteoarthritis (oa) of the hand is a major cause of pain and functional limitation, central sensitization of pain can be one of the causes: this hypothesis opens avenues for research in the modulation of pain pathways. the peripherally directed therapies may modulate pain perception bilaterally. this hypothesis opens avenues for future research in the modulation of pain pathways, perhaps offering targets to optimize peripheral manual and physical therapies for pain management in hand oa. several studies have reported the outcomes of multimodal approach to central sensitization evaluated by generalized pressure pain hypersensitivity in patients with carpometacarpal (cmc) oa. neurodynamic techniques are a form of manual therapy directed to the neural structures through positioning and movement of multiple joints. recent technologies have facilitated the use of robots as tools to assist patients in the rehabilitation process thus maximizing patient outcomes. these robotic tools assist the patient with carrying out exercise protocols, optimal for the activity of the control group.


Eligibility criteria:
inclusion criteria: * osteoarthritis of the dominant hand. to be included in the study, the subjects need to have a history of repetitive use of their dominant hand (eg, ex-factory worker) and a diagnosis of hand oa in the dominant hand, according on radiographic findings. exclusion criteria: * if they score greater than 6 points on the beck depression inventory (bdi) or more than 30 points in the state trait anxiety inventory (stai). patients with a medical history of carpal tunnel syndrome, surgical interventions to the hand, dequervain's tenosynovitis, or with degenerative or non-degenerative neurological conditions in which pain perception is altered will be excluded. none of the individuals in this study will have received prior interventions for hand oa.

Keywords: osteoarthritis hand rehabilitation
value of the laparoscopic approach in the surgical management of resectable hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: hepatocellular carcinoma treated by laparotomy or laparoscopic multicenter prospective, open, superiority, controlled, randomized, clinical trial the primary objective of the study will be to demonstrate the superiority of the laparoscopic approach over the open approach in reducing postoperative morbidity in hcc patients. postoperative morbidity will be assessed using the comprehensive complication index (cci) within 90 days postoperatively or at any time during hospitalization


Eligibility criteria:
inclusion criteria: * male or female patient aged ≥ 18 years * presenting with solitary or multifocal resectable hcc * qualifying for both pure laparoscopic and open approaches exclusion criteria: * physical or psychological status contraindicating the participation to the study * contraindication to surgery * contraindication to pneumoperitoneum * asa (american society of anesthesiologists) score iv-v * life expectancy \< 2 months * suspicion of mixed type tumor (hepatocholangiocarcinoma) and fibrolamellar hcc * child-pugh score \> b7 * extra-hepatic involvement * liver resection requiring an associated vascular or biliary reconstruction * pregnancy and breast-feeding * tutorship, trusteeship * concurrent participation in other experimental trials concerning the same objective within 90 days following intervention * no affiliation to the french social security * no ability to give their consent and not written informed consent

Keywords: laparoscopy laparotomy
ideal point of transluminal light in tracheal intubation with a light wand

Conditions: Neck Disease; Trismus; Tooth Abnormalities

Summary: if the patients's teeth are weak or the mouth dose not open well, the lightwand is a useful device when endotracheal intubation is necessary. therefore, if the appropriate position of the light beam is determined and the distance of the light source suitable for intubation using the lightwand is obtained from anatomical structures such as thyroid cartilage and cricoid cartilage, it is clinically useful. because it can prevent unnecessary deep insertion or shallow insertion that can cause damage to anatomical structures during intubation.

studies have been reported on the proper position to bend the lightwand and the appropriate angle to bend when performing endotracheal intubation with lightwand. for ease of procedure, the assistant has to lift the patient's lower jaw or perform a neck extension. however, there is no report on the position of the lightbulb when the light passes through the front of the airway and neck and appears bright in the midpoint. the prodcedure is as follows. 1. fob examination and check position of light below 1cm from vocal cord 2. lightwand intubation aimed at checkpoint 3. measurement of distance from thyroid cartilage/cricoid cartilage to light point

Eligibility criteria:
inclusion criteria: * impossibility of neck extension * trismus * weak teeth exclusion criteria: * previous history of larynx or neck surgery * no informed consent
effects of prophylactic massage therapy on pain tolerance and threshold

Conditions: Pain

Summary: therapeutic massage has been thought to reduce anxiety and increase relaxation in human patients.this study is meant to determine the immediate effects of therapeutic massage on pain tolerance and threshold.

patients participated in two trials of a pain stimulus test that measured pain threshold and pain tolerance. one trial was titled "massage protocol" and the other, "no-massage protocol." during the "massage protocol," they received a therapeutic massage to the forearm before participating in the pain stimulus test. during the "no-massage protocol" they did not receive a massage before participating in the pain stimulus test. their pain threshold and tolerance for both trials were compared against each other. each patient was randomized as to which protocol they participated in first.

Eligibility criteria:
inclusion criteria: -generally healthy exclusion criteria: * pregnant * smoker * cold allergy * raynaud's disease * cryophobia

Keywords: massage therapy pain tolerance pain threshold
external vacuum expansion: evaluation in breast reconstructive surgery evaluation in breast reconstructive surgery

Conditions: Breast Cancer Female

Summary: this multicentre randomized controlled trial aims to evaluate a new breast reconstruction technique- autologous fat transfer (aft). female patients with breast cancer schedule to receive a mastectomy (or having undergone mastectomy in the past) will be randomized to undergo breast reconstruction with either aft with the evebra device(intervention group) or aft without the evebra device (control group). aft will be evaluated in terms of volume, quality of life, aesthetic result, complications and oncological safety.


Eligibility criteria:
inclusion criteria: * female * age 23-69 * bmi 18-35 - stable weight, no fluctuations * have undergone a total mastectomy at least 3 months prior the study, whether therapeutic or prophylactic, whether unilateral or bilateral, with no resection of the pectoralis muscle * agrees to have reconstruction at the time of study involving only autologous fat grafting (aft) * assessed by surgeon to have enough donor fat * passes a 20-minutes tolerance test with evebra device. (patient will be fitted, instructed on the use, and given the evebra device to try in the office for 20 minutes. she passes if she tolerates its use, feels comfortable wearing it, and is able to comply with the required wear of the device.) exclusion criteria: * untreated breast cancer * history of radiation therapy on the involved breast, even if it was part of a previous breast conservation procedure * completed chemotherapy course less than 2 months prior (acceptable to still be on aromatase inhibitors) * except for the biopsy leading to the diagnosis of cancer, had surgery to breast prior to the mastectomy (e.g., multiple biopsies, implant augmentation, mastopexy, fat grating) * had mastectomy wound healing complications, e.g., seroma, wound breakdown, infection * mastectomy defect/scar has significant skin excess and deep folds adherent to the chest wall * has a pacemaker or aneurysm clips * pregnancy or breastfeeding * had a cardiac stent placed within the last 2 months * claustrophobic, as reported by patient * known current substance abuse, as reported by patient * history of silicone allergy, as reported by patient * history of gadolinium allergy, as reported by patient * history of lidocaine allergy, as reported by patient * bleeding diathesis, whether primary or iatrogenic, as reported by patient cigarette smoker and/or smokeless cigarette smokers, as reported by patient * medical conditions that preclude breast reconstruction including uncontrolled hypertension or diabetes, renal failure, steroid dependent asthma, and on immuno- suppressant medications, as reported by patient

Keywords: fat grafting lipoaspirate fat injection fat transfer lipofilling liposculpturing lipoinjection lipotransfer breast reconstruction external pre-expansion brava eve
necrotizing external otitis : study in a regional bone and joint infection reference center

Conditions: Bone and Joint Infection

Summary: the malignant external otitis is a rare disease which arises more frequently at the elderly and the diabetics patients. to our knowledge, there are few data and it is not wellc known byclinicians. nevertheless it exposes to neurological complications potentially serious and crippling.


Eligibility criteria:
inclusion criteria: * patients having had necrotizing external otitis and managed at the lyon bone and joint infection refence center exclusion criteria: * none

Keywords: otitis
continuous supraglottic aspiration in intubated and mechanically ventilated patients: the "supratube" device

Conditions: Aspiration Pneumonias

Summary: purpose of the trial: evaluate the efficacy and safety of the device of self-invention of continuous oropharyngeal aspiration denominated "supratube" in patients with orotracheal intubation and mechanical ventilation.


Eligibility criteria:
inclusion criteria: • endotracheal intubation and invasive mechanical ventilation, exclusion criteria: * immediate postoperative oral cavity. * traumatic oral cavity injury. * platelet count less than 50000.
multivisceral resections for locally advanced gastric cancer

Conditions: Gastric Cancer

Summary: the goal of this observational study is to assess whether the postoperative course and survival of patients subject to multivisceral resections for locally advanced gastric cancer (ct4b) were affected by the extent of surgery. an electronic database of 1476 patients with non-metastatic gastric cancer treated between january 1996 and december 2020 will be reviewed. the main questions it aims to answer are: * does splenectomy, distal pancreatectomy or partial colectomy affect postoperative complications * what factors affect prognosis of patients with locally advanced gastric cancer


Eligibility criteria:
inclusion criteria: * gastric adenocarcinoma * intraoperatively suspected infiltration of surrounding organs (stage ct4bn0-3bm0) * partial or total gastrectomy exclusion criteria: * distant metastases (m1) * gastrectomy combined with resection of organs other than spleen, pancreas, or colon

Keywords: gastric cancer locally advanced cancers multivisceral resections splenectomy pancreatectomy colectomy
a prospective comparative study between oncoplastic breast surgery and standard wide local excision

Conditions: Breast Cancer

Summary: the aim of this study is to asses the oncological safety of oncoplastic breast surgery, and its impact on patient satisfaction.

this non-randomized prospective trial was conducted on70 female patients presented to tertiary breast unit-ain shams university hospitals with breast cancer during the period from september 2012 to february 2013. all patients sharing in the study signed an informed consent that was approved in the ethical committee held on april 2012. patients were classified in two groups each one 35 patients: group (a) standard wide local excision and group (b) oncoplastic group. standard wide local excision done by general breast surgeons while oncoplastic surgeries done by breast surgeon assisted by plastic surgeon. the following data were recorded: age, family history, margin length, weight and volume of the specimen, margin status and patient satisfaction.

Eligibility criteria:
inclusion criteria: * patients with macromastia in oncoplastic group. * tumors \>20% of breast volume in oncoplastic group. * young patients in oncoplastic group * tumors in medial or central quadrants in oncoplastic group exclusion criteria: * patients \>60 years. * patients with co-morbidities in oncoplastic group. * tumors \>20% of breast volume in standard group. * tumors in medial or central quadrants in standard group

Keywords: oncoplastic breast surgery standard wide local excision
comparison of cefdinir and cefdinir/clavulanic acid combination in adults

Conditions: Acute Exacerbation of Chronic Bronchitis; Community-Acquired Pneumoniae

Summary: it is planned to compare the efficacy and safety of cefdinir and cefdinir/clavulanic acide treatments in acute exacerbation of chronic bronchitis (aecb) and community-acquired pneumoniae (cap) patients.


Eligibility criteria:
inclusion criteria: * the diagnosis of chronic bronchitis * the diagnosis of community-acquired pneumoniae * fev1 value = 30-80% * the diagnosis of mild-severe acute exacerbation of chronic bronchitis (aecb) * oxygen saturation \< 90% exclusion criteria: * pregnancy or breastfeeding * allergy against to penicillin or cephalosporins * renal impairment * active hepatic disease * antibiotic use except study drugs * immunosuppressive therapy before 6 months of study initiation * use of probenecid like drugs
patient-centered, optimal integration of survivorship and palliative care

Conditions: Stage IV Non-small Cell Lung Cancer; Targeted Therapy; Nonsmall Cell Lung Cancer; Carcinoma, Non-Small-Cell Lung; ALK-positive Non-small Cell Lung Cancer; EGFR Positive Non-small Cell Lung Cancer; Palliative Care; Survivorship

Summary: the goal of this study is to develop and test the feasibility of a supportive care model (poise) for patients with metastatic non-small cell lung cancer (nsclc). the main questions are * is poise feasible to deliver and acceptable to patients * what is the effect of poise on the distress patients feel related to their uncertain future, their confidence in their ability to manage cancer, and their understanding about what to expect participants in the randomized controlled trial will receive either the new supportive care model, poise, which consists of four visits with a trained palliative care clinician, or care as usual, and will be asked to complete three surveys.

this research study involves an intervention consisting of four sessions with palliative care specialists who have been additionally trained to evaluate and address the specific psychosocial issues and health-promoting behaviors of patients with nsclc. the research study procedures include: * four 60-minute visits with a trained palliative care clinician * questionnaires and an exit interview * chart review it is expected that about 70 participants currently receiving targeted therapy at massachusetts general hospital for lung cancer will take part in this research study: 10 patients in an open pilot study, followed by 60 patients in a randomized controlled trial.

Eligibility criteria:
inclusion criteria: * age 18 or older * mgh cancer center patient * within 6 months of diagnosis of metastatic nsclc with oncogenic driver mutation (egfr, alk, ros1, ret) * receiving targeted therapy * ability to respond in english or spanish exclusion criteria: * cognitive impairment or serious mental illness that limits ability to provide informed consent * need for urgent palliative care or hospice referral * pregnant women * prisoners

Keywords: stage iv non-small cell lung cancer targeted therapy nonsmall cell lung cancer carcinoma, non-small-cell lung alk-positive non-small cell lung cancer egfr positive non-small cell lung cancer ros1 positive non-small cell lung cancer palliative care survivorship ret fusion positive non-small cell lung cancer
a multiple dose study to evaluate the safety and efficacy of mk-2748 in hepatitis c-infected participants (mk-2748-002 am1)

Conditions: Hepatitis C

Summary: this is a multiple dose study of the safety and efficacy of mk-2748 to be done in 2 parts. part i will enroll genotype 1 (gt1) hepatitis c virus (hcv)-infected participants and part ii will enroll genotype 3 (gt3) hcv-infected participants. both parts may run concurrently or may be staggered.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of chronic hcv infection (gt1 or gt3) for at least 6 months and detectable hcv-rna in peripheral blood * body mass index (bmi) of 18 to 37 kg/m\^2 * no clinically significant abnormality on electrocardiogram (ecg) * stable health * willing to use appropriate contraception throughout the study and for 90 days after last dose of study drug exclusion criteria: * participant is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the study * history of stroke, chronic seizures, or major neurological disorder * history of clinically significant endocrine, gastrointestinal (excepting hcv infection), cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases * history of neoplastic disease (exceptions of adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix, or other malignancies which have been successfully treated ≥10 years prior and unlikely to recur * positive hepatitis b surface antigen * documented human immunodeficiency virus (hiv) infection * consumption of excessive amounts of alcohol, defined as greater than 2 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer \[284 ml/10 ounces\],wine \[125 ml/4 ounces\], or distilled spirits \[25 ml/1 ounce\]) per day * consumption of excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) or coffee, tea, cola, or other caffeinated beverages per day * major surgery, donated or lost 1 unit of blood (approximately 500 ml) within 4 weeks prior to study enrollment * history of significant multiple and/or severe allergies (including latex allergy), or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food * current regular user (including "recreational use") of any illicit drugs or history of drug (including alcohol) abuse within approximately 2 months prior to enrollment * evidence or history of chronic hepatitis not caused by hcv including but not limited to non-hcv viral hepatitis, non-alcoholic steatohepatitis (nash), drug induced hepatitis, autoimmune hepatitis * previous treatment with other hcv ns3/4a protease inhibitors * previous exposure to interferon-alpha and/or ribavirin within 3 months prior to study enrollment * clinical or laboratory evidence of advanced or decompensated liver disease; evidence of bridging fibrosis or higher grade fibrosis (metavir score ≥3) * participation in another investigational study within 4 weeks prior to enrollment
measurement of urinary catabolites of pacs as biomarkers of consumption of cranberry extracts

Conditions: Urinary Tract Infections

Summary: the purpose of this cross over pilot study is to investigate the urinary catabolites of proanthocyanidines (pacs) as biomarkers of cranberry extracts in healthy young women.


Eligibility criteria:
inclusion criteria: * healthy women. * 18 to 40 years. exclusion criteria: * no internet access. * no refrigerator access during the 9 hours of sample collection. * women who had or expect to take antibiotic. * women who had or expect to take cranberries, blueberries or bilberries in the form of berries, juice or extracts. * women who had or expect to take dark chocolate. * women who had personal history of acute or chronic renal failure.

Keywords: cranberry proanthocyanidins urinary catabolites
a multicenter, randomized, double-blind parallel-group, placebo-controlled efficacy study comparing 4 weeks of treatment with esomeprazole 20 mg once daily to placebo qd for the resolution of upper abdominal pain in patients with symptomatic gastroesophageal reflux disease (sgerd)

Conditions: Symptomatic Gastroesophageal Reflux Disease (sGERD)

Summary: this study compares 4 weeks of treatment with esomeprazole 20 mg once daily to placebo in the treatment of upper abdominal pain in patients with symptomatic gastroesophageal reflux disease (sgerd)


Eligibility criteria:
inclusion criteria: * history of episodes of heartburn and upper abdominal pain for 6 months or longer. * episodes of heartburn 2 or more days during the 7 days prior to the screening visit. moderate or severe upper abdominal pain on at least 3 out of the 7 consecutive days of the run-in period. * a normal endoscopy within 14 days of visit 1 of between run-in and randomization. exclusion criteria: * subjects with pain likely to be due to irritable bowel syndrome (ibs) * history of esophageal, gastric or duodenal surgery, except for closure of an ulcer. * history of severe liver disease, including (but not limited to) cirrhosis and acute or chronic hepatitis. * further diseases / conditions, as listed in the protocol.

Keywords: symptomatic gastroesophageal reflux disease (sgerd) nexium esomeprazole